JPRN-jRCT2080221924CompletedPhase 1
Phase 1 Clinical Study of JTZ-951 - Clinical Pharmacology study
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Japan Tobacco Inc.
- Enrollment
- 6
Study Overview
Brief Summary
After single oral dose administration of JTZ-951 in CKD patients receiving maintenance hemodialysis, JTZ-951 was absorbed rapidly and the plasma concentration declined in a biphasic manner. Single-dose administration of JTZ-951 was well tolerated.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 74age old (—)
- Sex
- All
Inclusion Criteria
- •Patients undergoing hemodialysis consistently 3 times weekly
- •-Dry weight between 35kg and 70kg
Exclusion Criteria
- •-Systolic blood pressure of 180 mmHg or more and diastolic blood pressure of 110 mmHg or more
- •-Patients with congestive heart failure
- •-Patients with malignancy
Investigators
Similar Trials
Completed
Phase 2
An Early Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction study>Anemia with CKDJPRN-jRCT2080222207Japan Tobacco Inc.40
Completed
Phase 2
An Early Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Anemia Correction study>Anemia with CKDJPRN-jRCT2080222246Japan Tobacco Inc.22
Completed
Phase 1
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal ImpairmentRenal ImpairmentInsomniaNCT06671444Shanghai Haiyan Pharmaceutical Technology Co., Ltd.16
Completed
Phase 2
ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Receiving Maintenance Hemodialysis <Anemia Correction / Maintenance Study>Anemia with CKDJPRN-jRCT2080222839Japan Tobacco Inc.71
Completed
Phase 2
ate Phase 2 Study of JTZ-951 in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis <Anemia Correction / Switch / Maintenance Study>Anemia with CKDJPRN-jRCT2080222829Japan Tobacco Inc.201